Skip to main content

Advertisement

Table 5 Comparing patients with or without interstitial lung disease

From: Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study

  Patients with ILD Patients without ILD P value
(n = 61) (n = 95)
Male/female 28/33 33/62 0.16
Mean (median) age (years) 69.3 ± 1.6 (71) 67.3 ± 1.3 (71) 0.26
MPO-ANCA 60 (98.3) 70 (73.7) <0.001
PR3-ANCA 3 (4.9) 15 (15.8) 0.038
Serum creatinine (mg/dl) 1.61 ± 0.23 1.83 ± 0.19 0.45
Disease severity 0.059
 Localised 1 (1.7) 3 (3.1)  
 Early systemic 21 (34.4) 15 (15.8)  
 Generalised 31 (50.8) 60 (63.2)  
 Severe 8 (13.1) 17 (17.9)  
General performancea
 0/1/2/3/4 11/25/11/12/2 11/33/17/28/6 0.47
BVASb
 BVAS 15.4 ± 1.0 18.4 ± 0.8 0.019
 General 49 (80.3) 69 (72.6) 0.27
 Cutaneous 13 (21.3) 26 (27.4) 0.39
 Mucous membranes/eyes 5 (8.2) 15 (15.8) 0.17
 Ear, nose, and throat 9 (14.8) 33 (34.7) 0.006
 Chest 22 (36.1) 41 (43.2) 0.38
 Cardiovascular 1 (1.7) 11 (11.6) 0.012
 Abdominal 0 (0) 2 (2.1) 0.25
 Renal 44 (72.1) 65 (68.4) 0.62
 Nervous system 28 (45.9) 47 (49.5) 0.66
  1. Values expressed as mean ± standard error or number (percentage) unless otherwise noted. ANCA, antineutrophil cytoplasmic antibody; BVAS, Birmingham Vasculitis Activity Score; ILD, interstitial lung disease; MPO, myeloperoxidase; MPA, microscopic polyangiitis; PR3, proteinase-3. aGeneral performance was categorised according to the World Health Organization Performance Status except category 5 (death). bDisease activity and patterns of organ involvement were defined by the BVAS 2003 scoring system.